What this is
- How it works
- How it works isn't classified yet
- Tested for
- Essential Hypertension
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension”In the company’s words, NCT06441630 on ClinicalTrials.gov
Other drugs for Essential Hypertension
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- Valsartan Oral SolutionShandong New Time Pharmaceutical Co., LTD · Phase 3
- AD-227BAddpharma Inc. · Phase 3
- QR12000Wuhan Createrna Science and Technology Co., Ltd · Phase 3
- Sacubitril∙ValsartanChong Kun Dang Pharmaceutical · Phase 3
- BR1400-1Boryung Pharmaceutical Co., Ltd · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Sep 2025 | A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B | |
| Phase 1Completed | 13 Aug 2025 | A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026